These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21890793)

  • 1. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD.
    Vitiello B; Elliott GR; Swanson JM; Arnold LE; Hechtman L; Abikoff H; Molina BS; Wells K; Wigal T; Jensen PS; Greenhill LL; Kaltman JR; Severe JB; Odbert C; Hur K; Gibbons R
    Am J Psychiatry; 2012 Feb; 169(2):167-77. PubMed ID: 21890793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the effect of ADHD stimulant medication on heart rate and blood pressure in a community sample of children?
    St Amour MD; O'Leary DD; Cairney J; Wade TJ
    Can J Public Health; 2018 Jun; 109(3):395-400. PubMed ID: 29981090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.
    Molina BS; Hinshaw SP; Eugene Arnold L; Swanson JM; Pelham WE; Hechtman L; Hoza B; Epstein JN; Wigal T; Abikoff HB; Greenhill LL; Jensen PS; Wells KC; Vitiello B; Gibbons RD; Howard A; Houck PR; Hur K; Lu B; Marcus S;
    J Am Acad Child Adolesc Psychiatry; 2013 Mar; 52(3):250-63. PubMed ID: 23452682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
    Hennissen L; Bakker MJ; Banaschewski T; Carucci S; Coghill D; Danckaerts M; Dittmann RW; Hollis C; Kovshoff H; McCarthy S; Nagy P; Sonuga-Barke E; Wong IC; Zuddas A; Rosenthal E; Buitelaar JK;
    CNS Drugs; 2017 Mar; 31(3):199-215. PubMed ID: 28236285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate?
    Wigal SB; Jun A; Wong AA; Stehli A; Steinberg-Epstein R; Lerner MA
    Postgrad Med; 2010 Sep; 122(5):27-34. PubMed ID: 20861585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].
    Bange F; Le Heuzey MF; Acquaviva E; Delorme R; Mouren MC
    Arch Pediatr; 2014 Jan; 21(1):108-12. PubMed ID: 24309201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder.
    Sayer GR; McGough JJ; Levitt J; Cowen J; Sturm A; Castelo E; McCracken JT
    J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):882-888. PubMed ID: 27483130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic profile and behavioral characteristics during induction of anesthesia in pediatric patients with attention deficit hyperactivity disorder.
    Cartabuke RS; Tobias JD; Rice J; Tumin D
    Paediatr Anaesth; 2017 Apr; 27(4):417-424. PubMed ID: 28181385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.
    Arch Gen Psychiatry; 1999 Dec; 56(12):1073-86. PubMed ID: 10591283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.
    Wilens TE; Hammerness PG; Biederman J; Kwon A; Spencer TJ; Clark S; Scott M; Podolski A; Ditterline JW; Morris MC; Moore H
    J Clin Psychiatry; 2005 Feb; 66(2):253-9. PubMed ID: 15705013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD.
    Weisler RH; Biederman J; Spencer TJ; Wilens TE
    CNS Spectr; 2005 Dec; 10(12 Suppl 20):35-43. PubMed ID: 16344839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy.
    Stowe CD; Gardner SF; Gist CC; Schulz EG; Wells TG
    Ann Pharmacother; 2002; 36(7-8):1142-9. PubMed ID: 12086544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults.
    Mick E; McManus DD; Goldberg RJ
    Eur Neuropsychopharmacol; 2013 Jun; 23(6):534-41. PubMed ID: 22796229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder.
    Arch Gen Psychiatry; 1999 Dec; 56(12):1088-96. PubMed ID: 10591284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADHD pharmacotherapy: rates of stimulant use and cardiovascular risk.
    Kratochvil CJ
    Am J Psychiatry; 2012 Feb; 169(2):112-4. PubMed ID: 22318789
    [No Abstract]   [Full Text] [Related]  

  • 17. Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy.
    Eaton C; Yong K; Walter V; Mbizvo GK; Rhodes S; Chin RF
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD013136. PubMed ID: 35844168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Sleep Problems Across Attention-Deficit/Hyperactivity Disorder Treatment: Findings from the Multimodal Treatment of Attention-Deficit/Hyperactivity Disorder Study.
    Ricketts EJ; Sturm A; McMakin DL; McGuire JF; Tan PZ; Smalberg FB; McCracken JT; Colwell CS; Piacentini J
    J Child Adolesc Psychopharmacol; 2018 Dec; 28(10):690-698. PubMed ID: 30388029
    [No Abstract]   [Full Text] [Related]  

  • 19. An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension.
    Wilens TE; Zusman RM; Hammerness PG; Podolski A; Whitley J; Spencer TJ; Gignac M; Biederman J
    J Clin Psychiatry; 2006 May; 67(5):696-702. PubMed ID: 16841618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
    Martinez-Raga J; Knecht C; Szerman N; Martinez MI
    CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.